



Modified Form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/872,968
Filing Date	June 1, 2001
First Named Inventor	Jack R. Wands
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	21486-047

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
de	AA	5,800,390	09/1/98	Hayakawa et al.	604	93	
	AB	5,863,898	01/26/99	Goli et al.	514	12	
	AC	6,071,075	06/6/00	Tomita et al.	416	97	
de	AD	6,180,784 B1	01/30/01	Wolff et al.	540	474	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
de	BA	WO 98/38204 ✓	de la Monte et al.	09/3/98		
de	BB	WO 96/15272 ✓	de la Monte et al.	05/23/96		
de	BC	WO 94/23756 ✓	de la Monte et al.	10/27/94		


OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
de	CA	Czubayko et al., "Ribozyme-Elucidates a Direct Role of Pleiotrophin in Tumor Growth," 1994, J. Biol. Chem. 269:21358-21363
	CB	de la Monte et al., "Microtiter Immunocytochemical ELISA Assay", 1999, Biotechniques 26:1073-1076
	CC	de la Monte et al., "Characterization of the AD7C-NTP cDNA Expression in Alzheimer's Disease and Measurement of a 41-kD Protein in Cerebrospinal Fluid," 1997, J. Clin. Invest. 100(12):30393-3104
	CD	de la Monte et al., "Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration," Neurobiol. Aging, 2000 Mar-April; 21(2): 309-319.
	CE	GENBANK™ Accession No. NM014486
	CF	GENBANK™ Accession No. AF010144
	CG	Kobayashi et al., "Reversal of Drug Sensitivity in Multi-Resistant Tumor Cells by an MDR1 (PGY1) Ribozyme," 1994, Cancer Res. 54:1271-1275
de	CH	Mahieu et al., "Construction of a Ribozyme Directed Against Human Interleukin-6 mRNA: Evaluation of Its Catalytic Activity In Vitro and In Vivo," 1994, Blood 84:3758-65

Examiner Signature	Deborah Crone	Date Considered	11-14-02
--------------------	---------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/872,968
	Filing Date	June 1, 2001
	First Named Inventor	Jack R. Wands
	Group Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
	Attorney Docket Number	21486-047

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

OTHER NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
DL	CI	Melani et al., "Inhibition of Proliferation by c-myc Antisense Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines That Express c-myc," Cancer Res. 51:2897-2901, 1991.	
DL	CJ	Quon et al, Formation of β -Amyloid Protein Deposits in Brains of Transgenic Mice. Nature, 18 July 1991, vol. 352, pages 239-241.	
DL	CK	Sullivan et al., "Development of Ribozymes for Gene Therapy," 1994, J. Invest. Derm. 103:85S-89S	
Examiner Signature		<i>Deborah Crum</i>	Date Considered 11-14-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRADOCS:1421558.1(%GVQ011.DOC)

TRA 1531598v1